The Obesity Treatment Market
Outlook And Analysis by Type (Inactivity,
Obesity gluten, Obesity), Diagnosis (Blood Tests, Physical Examination),
Treatment (Medication, Surgery, Lifestyle Changes), End-Users (Hospitals,
Clinics) - Forecast Till 2030
Market Research Future (MRFR), while
discussing the possibilities of the global market for obesity treatment,
predicted rise by 16.70% during the forecast period. This growth will depend a
lot on the changes in weight loss and weight management market.
Drivers and Restraints:
The obesity treatment market will depend on aspects like the rising awareness, a surge
in the number of health-conscious people, better inclusion rate for latest
technologies, a hike in investment for research and development, innovations
and their speedy approval, awaiting products in the pipeline, a surge in
disposable income, changing food habits, and others. In developing countries,
this growth is getting backed by strategies launched by top brands to ensure
their expansion.
However, the obesity treatment market
share may find some roadblocks in the form of a sedentary lifestyle that has
been enforced on people by rapidly increasing industrialization and
urbanization.
Segmentation:
The global obesity treatment market
has been studied by MRFR on the basis of a type, diagnosis, treatment, and
end-user. These segments and data in them are expected to facilitate the
decision-making process for the future.
By type, the obesity treatment market
has been studied on the basis of food obesity, anxiety obesity, inactivity
obesity, atherogenic obesity, venous obesity, and gluten obesity.
By diagnosis, the report containing
details of the treatment for obesity market share has
been segmented into physical examination, blood tests, and others. The blood
tests segment includes thyroid test, liver function test, cholesterol test, and
others. The physical examination segment comprises blood pressure measurement,
heart rate measurement, and others.
By treatment, the study on the global
obesity treatment market includes surgery, medication, lifestyle changes, and
others. The medication segment has been studied on the basis of lorcaserin,
orlistat, liraglutide, phentermine and topiramate, and others. The surgery
segment includes Laparoscopic Adjustable Gastric Banding (LAGB), gastric bypass
surgery, biliopancreatic diversion, gastric sleeve, gastric sleeve, and
others.
By end-user, the report on the obesity
treatment market includes clinics, pharmacies, hospitals, and others.
Regional Analysis:
The Americas is slated to take the
lead of the global market during the forecast period by maintaining a steady
flow of investment, increasing awareness, and funding various research
projects. The US and Canada would impact the market the most. In Asia Pacific,
the growth would experience traction from rising disposable income.
Competitive Landscape:
Arena Pharmaceuticals, Inc. (U.S.),
VIVUS, Inc. (U.S.), Novo Nordisk A/S (Denmark), Orexigen Therapeutics, Inc.
(U.S.), F. Hoffmann-La Roche, Ltd. (Switzerland), Cousin Biotech (France),
EnteroMedics, Inc. (U.S.), Allergan (Republic of Ireland), Olympus Corporation
(Japan), Medtronic (U.S.), USGI Medical, Inc. (U.S.), Johnson & Johnson
Services, Inc. (U.S.), Covidien plc (Republic of Ireland), Mediflex Surgical
Products (U.S.), and others are some of the major companies impacting the
obesity treatment market trends and outcomes.
Industry News:
In June 2020, researchers from the
Pennington Biomedical Research Center in Baton Rouge, LA, declared that they
had discovered BAM15. This is a protein that can have a significant impact on
the potential treatment for obesity and it can help in curbing the impact of
related diseases. BAM15 increases mitochondrial respiration and other sustained
activity in major ways, it does not impact food consumption but reduces the
influence of mitochondria.
In June 2020, Novo Nordisk declared
the results of two clinical trials with a phase 2 monotherapy trial and a phase
1 combination trial of AM833, a novel once-weekly subcutaneous amylin analogue
(AM833), and once-weekly subcutaneous semaglutide 2.4 mg. This test was
conducted to understand obesity or overweight that have at least one
weight-related comorbidity.
About Market
Research Future:
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact
us:
Market
Research Future (part of Wantstats Research and Media Private Limited),
99
Hudson Street, 5Th Floor,
New
York, New York 10013
United
States of America
+1 628
258 0071
Email:
sales@marketresearchfuture.com
Comments
Post a Comment